PC-3

PC-3是用於前列腺癌研究和藥物開發的人類前列腺癌細胞系，最初是在1979年分離自一名62歲白人男性的前列腺癌患者^[1]。

特徵

PC-3細胞睪丸激素 5α還原酶及酸性磷酸酶的活性低，並且不會表達前列腺特異抗原。有核型分析報告表明PC-3細胞是近三倍體的，具有62條染色體，當中並沒有Y染色體的存在。電子顯微鏡顯示PC-3細胞表現出低分化腺癌的特徵，並且具有上皮起源的贅生性細胞共有的特徵，例如許多微絨毛、接合複合物、異常的細胞核、核仁及粒線體、環孔片層（英語：Annulate lamella）及脂質體。這些細胞對雄激素、糖皮質激素及成纖維細胞生長因子並沒有任何反應^[2]，但有研究表明該細胞會受表皮生長因子所影響^[3]。這些細胞可在小鼠中建立皮下腫瘤異種移植物，以研究腫瘤環境和治療藥物功能。PC-3細胞可用於研究晚期前列腺癌細胞的生化變化，以及評估其對化學治療劑的反應。 PC-3細胞還用於研究表現出免疫反應的哺乳動物細胞中的病毒感染^[4]。與具有中等轉移潛能的DU145細胞和具有低轉移潛能的LNCaP細胞相比，PC-3細胞具有較高的轉移潛能^[5]。

另見

DU145
LNCaP

參考資料

^ Kaighn, ME; Narayan, KS; Ohnuki, Y; Lechner, JF; Jones, LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3).. Investigative urology. 1979-07, 17 (1): 16–23 [2020-01-13]. PMID 447482. （原始內容存檔於2020-01-13）.
^ Tai, S; Sun, Y; Squires, JM; Zhang, H; Oh, WK; Liang, CZ; Huang, J. PC3 is a cell line characteristic of prostatic small cell carcinoma.. The Prostate. 2011-11, 71 (15): 1668–79 [2020-01-13]. PMID 21432867. doi:10.1002/pros.21383. （原始內容存檔於2020-01-13）.
^ Johnston, ST; Shah, ET; Chopin, LK; Sean McElwain, DL; Simpson, MJ. Estimating cell diffusivity and cell proliferation rate by interpreting IncuCyte ZOOM™ assay data using the Fisher-Kolmogorov model.. BMC systems biology. 2015-07-19, 9: 38 [2020-01-13]. PMID 26188761. doi:10.1186/s12918-015-0182-y. （原始內容存檔於2020-01-13）.
^ Timm, C; Gupta, A; Yin, J. Robust kinetics of an RNA virus: Transcription rates are set by genome levels.. Biotechnology and bioengineering. 2015-08, 112 (8): 1655–62 [2020-01-13]. PMID 25726926. doi:10.1002/bit.25578. （原始內容存檔於2020-01-13）.
^ Pulukuri, SM; Gondi, CS; Lakka, SS; Jutla, A; Estes, N; Gujrati, M; Rao, JS. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.. The Journal of biological chemistry. 2005-10-28, 280 (43): 36529–40 [2020-01-13]. PMID 16127174. doi:10.1074/jbc.M503111200. （原始內容存檔於2020-01-13）.

外部連結

Cellosaurus entry for PC-3（頁面存檔備份，存於網際網路檔案館）

[1] Kaighn, ME; Narayan, KS; Ohnuki, Y; Lechner, JF; Jones, LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3).. Investigative urology. 1979-07, 17 (1): 16–23 [2020-01-13]. PMID 447482. （原始內容存檔於2020-01-13）.

[a-2] Tai, S; Sun, Y; Squires, JM; Zhang, H; Oh, WK; Liang, CZ; Huang, J. PC3 is a cell line characteristic of prostatic small cell carcinoma.. The Prostate. 2011-11, 71 (15): 1668–79 [2020-01-13]. PMID 21432867. doi:10.1002/pros.21383. （原始內容存檔於2020-01-13）.

[3] Johnston, ST; Shah, ET; Chopin, LK; Sean McElwain, DL; Simpson, MJ. Estimating cell diffusivity and cell proliferation rate by interpreting IncuCyte ZOOM™ assay data using the Fisher-Kolmogorov model.. BMC systems biology. 2015-07-19, 9: 38 [2020-01-13]. PMID 26188761. doi:10.1186/s12918-015-0182-y. （原始內容存檔於2020-01-13）.

[4] Timm, C; Gupta, A; Yin, J. Robust kinetics of an RNA virus: Transcription rates are set by genome levels.. Biotechnology and bioengineering. 2015-08, 112 (8): 1655–62 [2020-01-13]. PMID 25726926. doi:10.1002/bit.25578. （原始內容存檔於2020-01-13）.

[5] Pulukuri, SM; Gondi, CS; Lakka, SS; Jutla, A; Estes, N; Gujrati, M; Rao, JS. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.. The Journal of biological chemistry. 2005-10-28, 280 (43): 36529–40 [2020-01-13]. PMID 16127174. doi:10.1074/jbc.M503111200. （原始內容存檔於2020-01-13）.

[1]

[2]

[3]

[4]

[5]